JP6026402B2 - Ｈｉｖの伝染を抑制する方法及び組成物 - Google Patents

Ｈｉｖの伝染を抑制する方法及び組成物 Download PDF

Info

Publication number
JP6026402B2
JP6026402B2 JP2013502959A JP2013502959A JP6026402B2 JP 6026402 B2 JP6026402 B2 JP 6026402B2 JP 2013502959 A JP2013502959 A JP 2013502959A JP 2013502959 A JP2013502959 A JP 2013502959A JP 6026402 B2 JP6026402 B2 JP 6026402B2
Authority
JP
Japan
Prior art keywords
hiv
clade
env
colostrum
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013502959A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523783A (ja
JP2013523783A5 (enExample
Inventor
ローリン，グラント，トーマス
パーセル，ダミアン，フランシス，ジョン
センター，ロバート，ジョン
クラムスキー，マリット
ロビンス−ブローニー，ロイ，マイケル
リクティ，ゴットフリード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immuron Ltd
Original Assignee
Immuron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuron Ltd filed Critical Immuron Ltd
Publication of JP2013523783A publication Critical patent/JP2013523783A/ja
Publication of JP2013523783A5 publication Critical patent/JP2013523783A5/ja
Application granted granted Critical
Publication of JP6026402B2 publication Critical patent/JP6026402B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2013502959A 2010-04-09 2011-04-11 Ｈｉｖの伝染を抑制する方法及び組成物 Expired - Fee Related JP6026402B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32239910P 2010-04-09 2010-04-09
US61/322,399 2010-04-09
PCT/AU2011/000407 WO2011123900A1 (en) 2010-04-09 2011-04-11 Methods and compositions for inhibiting hiv transmission

Publications (3)

Publication Number Publication Date
JP2013523783A JP2013523783A (ja) 2013-06-17
JP2013523783A5 JP2013523783A5 (enExample) 2014-05-29
JP6026402B2 true JP6026402B2 (ja) 2016-11-16

Family

ID=44761932

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013502959A Expired - Fee Related JP6026402B2 (ja) 2010-04-09 2011-04-11 Ｈｉｖの伝染を抑制する方法及び組成物

Country Status (12)

Country Link
US (1) US20130022619A1 (enExample)
EP (1) EP2555798B1 (enExample)
JP (1) JP6026402B2 (enExample)
CN (1) CN103167881B (enExample)
AP (1) AP3469A (enExample)
AU (2) AU2011238431B2 (enExample)
BR (1) BR112012025678A2 (enExample)
CA (1) CA2795853A1 (enExample)
MX (1) MX343505B (enExample)
RU (1) RU2594249C2 (enExample)
WO (1) WO2011123900A1 (enExample)
ZA (1) ZA201207790B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2925471A1 (en) 2013-09-27 2015-04-02 Duke University Hiv-1 mother-to-child transmission correlates of protection and vaccine
CN103736100B (zh) * 2013-12-25 2017-06-09 南方医科大学 预防hiv性传播的杀微生物剂酸酐修饰抗sevi多克隆抗体
PH12018500645B1 (en) * 2015-09-24 2022-10-21 Abvitro Llc Hiv antibody compositions and methods of use
WO2017062070A1 (en) * 2015-10-07 2017-04-13 Eca Medical Instruments Gearless compact torque drive
US10973679B2 (en) * 2016-02-12 2021-04-13 Adam Arreola STD detecting condom
AU2021289612A1 (en) * 2020-06-10 2023-01-19 The University Of Melbourne HIV-1 antibodies
US20240218052A1 (en) 2021-05-12 2024-07-04 Applied Biomedical Science Institute Methods of screening and expression of disulfide-bonded binding polypeptides
US20240262893A1 (en) 2021-05-12 2024-08-08 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
JP7421610B1 (ja) 2022-08-18 2024-01-24 株式会社マーベラス ゲーム装置
EP4619430A1 (en) 2022-11-16 2025-09-24 Applied Biomedical Science Institute Fusion polypeptides and binding peptides and methods for producing and using same
WO2026073047A1 (en) 2024-09-27 2026-04-02 Applied Biomedical Science Institute Methods of screening and expressing cis-display libraries of disulfide-rich polypeptides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039957A (en) * 1993-12-10 2000-03-21 United States Of America, As Represented By The Department Of Health And Human Services Oligomeric HIV-1 envelope glycoproteins
HK1047300A1 (zh) * 1999-06-24 2003-02-14 The Johns Hopkins University 预防经上皮传染hiv的组合物与方法
WO2002026212A2 (en) * 2000-09-28 2002-04-04 Chiron Corporation Microparticle compositions and methods for the manufacture thereof
CA2667358A1 (en) * 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
CA2704059A1 (en) * 2007-10-30 2009-05-07 International Aids Vaccine Initiative Antigen-antibody complexes as hiv-1 vaccines
CA2739905A1 (en) * 2008-10-30 2010-08-26 Dana-Farber Cancer Institute Mimotopes of hiv env

Also Published As

Publication number Publication date
AU2017265055A1 (en) 2019-06-06
EP2555798A4 (en) 2013-11-20
RU2594249C2 (ru) 2016-08-10
MX2012011574A (es) 2013-03-05
JP2013523783A (ja) 2013-06-17
AU2011238431B2 (en) 2016-10-06
MX343505B (es) 2016-11-04
RU2012142999A (ru) 2014-05-20
EP2555798A1 (en) 2013-02-13
US20130022619A1 (en) 2013-01-24
CA2795853A1 (en) 2011-10-13
EP2555798B1 (en) 2016-06-22
WO2011123900A1 (en) 2011-10-13
ZA201207790B (en) 2013-06-26
AU2011238431A1 (en) 2012-11-08
AP2012006519A0 (en) 2012-10-31
CN103167881A (zh) 2013-06-19
BR112012025678A2 (pt) 2017-07-18
CN103167881B (zh) 2017-06-16
AP3469A (en) 2015-11-30

Similar Documents

Publication Publication Date Title
AU2011238431B2 (en) Methods and compositions for inhibiting HIV transmission
Morein et al. Current status and potential application of ISCOMs in veterinary medicine
TWI320715B (en) Improved mycoplasma hyopneumoniae bacterin vaccine
RU2407749C2 (ru) Иммуногенная композиция и способ разработки вакцины, основанной на слитом белке
US7262270B2 (en) Fusion protein construct and method for inducing HIV-specific serum IgG and secretory IgA antibodies in-vivo
Machado et al. Adaptive immunity in the postpartum uterus: Potential use of vaccines to control metritis
JP2020097569A (ja) 競合的ｈｉｖ侵入阻害を媒介するｃｄ４に対するモノクローナル抗体によるｈｉｖ感染の処置および機能的治癒
Yuki et al. Progress towards an AIDS mucosal vaccine: an overview
US20200140529A1 (en) Methods and compositions for inhibiting hiv transmission
AU2021204628B2 (en) Methods and compositions related to accelerated humoral affinity
US20240277829A1 (en) Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
Zinckgraf et al. Antibody responses to a mucosally delivered HIV-1 gp120-derived C4/V3 peptide
CN108368260A (zh) 含有角鲨烯的基于两亲性聚氨基酸聚合物的疫苗佐剂组合物
Morris MA (Cantab.), MBBS (Lond.), MRCP (UK)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150626

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160520

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160822

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160913

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161012

R150 Certificate of patent or registration of utility model

Ref document number: 6026402

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees